EYEPOINT PHARMACEUTICALS, INC Shares Outstanding 2006-2021 | EYPT

EYEPOINT PHARMACEUTICALS, INC shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
EYEPOINT PHARMACEUTICALS, INC Annual Shares Outstanding
(Millions of Shares)
2020 13
2019 10
2018
2018 5
2017 4
2016 3
2015 3
2014 3
2013 2
2012 2
2011 2
2010 2
2009 2
2008 2
2007
2007 1
2006
2006 1
2005 2
EYEPOINT PHARMACEUTICALS, INC Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 29
2021-03-31 25
2020-12-31 13
2020-09-30 13
2020-06-30 12
2020-03-31 12
2019-12-31 10
2019-09-30 11
2019-06-30 11
2019-03-31 10
2018-12-31
2018-09-30 8
2018-06-30 6
2018-03-31 5
2017-12-31 4
2017-09-30 4
2017-06-30
2017-03-31 3
2016-12-31 3
2016-09-30 3
2016-06-30
2016-03-31 3
2015-12-31 3
2015-09-30 3
2015-06-30
2015-03-31 3
2014-12-31 3
2014-09-30 3
2014-06-30
2014-03-31 3
2013-12-31 3
2013-09-30 3
2013-06-30
2013-03-31 2
2012-12-31 2
2012-09-30 2
2012-06-30
2012-03-31 2
2011-12-31 2
2011-09-30 2
2011-06-30
2011-03-31 2
2010-12-31 2
2010-09-30 2
2010-06-30
2010-03-31 2
2009-12-31 2
2009-09-30 2
2009-06-30
2009-03-31 2
2008-12-31 2
2008-09-30 2
2008-06-30
2008-03-31 2
2007-12-31 2
2007-09-30 2
2007-06-30
2007-03-31 11
2006-12-31 10
2006-09-30 10
2006-06-30
2005-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.330B $0.034B
EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known as pSivida Corp., is headquartered in Watertown, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29